The Cost of Oncology Medicines

Cancer as a financial value is one of the most expensive diseases. Costs, including the cost of new cancer drugs, are increasing at an unsustainable rate, threatening the permanent access of patients to treatment. Prices for new treatments against cancer have doubled over the past 10 years and now a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zlatareva A., Krahtova K., Kazak Tch.
Formato: article
Lenguaje:EN
Publicado: Sciendo 2017
Materias:
R
Acceso en línea:https://doaj.org/article/daa014a67d3b486ba09f2774187ae8b2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:daa014a67d3b486ba09f2774187ae8b2
record_format dspace
spelling oai:doaj.org-article:daa014a67d3b486ba09f2774187ae8b22021-12-02T17:31:48ZThe Cost of Oncology Medicines0324-175010.1515/amb-2017-0004https://doaj.org/article/daa014a67d3b486ba09f2774187ae8b22017-05-01T00:00:00Zhttps://doi.org/10.1515/amb-2017-0004https://doaj.org/toc/0324-1750Cancer as a financial value is one of the most expensive diseases. Costs, including the cost of new cancer drugs, are increasing at an unsustainable rate, threatening the permanent access of patients to treatment. Prices for new treatments against cancer have doubled over the past 10 years and now are usually between USD 6000 and USD 10,000 per month, this increase is often not correlated with reimbursement and implemented public health benefits. According to various authors, these results lead to debate whether the cost differences between EU countries and the US for the treatment of oncologic diseases are transformed into improved outcomes for patients, and must also take into account key factors such as lifestyle, late diagnosis, and management approach for treatment, reimbursement of oncology treatment and control of various institutions on spending.Zlatareva A.Krahtova K.Kazak Tch.Sciendoarticlepharmacotherapy costoncologic diseasescancertreatmentMedicineRENActa Medica Bulgarica, Vol 44, Iss 1, Pp 22-29 (2017)
institution DOAJ
collection DOAJ
language EN
topic pharmacotherapy cost
oncologic diseases
cancer
treatment
Medicine
R
spellingShingle pharmacotherapy cost
oncologic diseases
cancer
treatment
Medicine
R
Zlatareva A.
Krahtova K.
Kazak Tch.
The Cost of Oncology Medicines
description Cancer as a financial value is one of the most expensive diseases. Costs, including the cost of new cancer drugs, are increasing at an unsustainable rate, threatening the permanent access of patients to treatment. Prices for new treatments against cancer have doubled over the past 10 years and now are usually between USD 6000 and USD 10,000 per month, this increase is often not correlated with reimbursement and implemented public health benefits. According to various authors, these results lead to debate whether the cost differences between EU countries and the US for the treatment of oncologic diseases are transformed into improved outcomes for patients, and must also take into account key factors such as lifestyle, late diagnosis, and management approach for treatment, reimbursement of oncology treatment and control of various institutions on spending.
format article
author Zlatareva A.
Krahtova K.
Kazak Tch.
author_facet Zlatareva A.
Krahtova K.
Kazak Tch.
author_sort Zlatareva A.
title The Cost of Oncology Medicines
title_short The Cost of Oncology Medicines
title_full The Cost of Oncology Medicines
title_fullStr The Cost of Oncology Medicines
title_full_unstemmed The Cost of Oncology Medicines
title_sort cost of oncology medicines
publisher Sciendo
publishDate 2017
url https://doaj.org/article/daa014a67d3b486ba09f2774187ae8b2
work_keys_str_mv AT zlatarevaa thecostofoncologymedicines
AT krahtovak thecostofoncologymedicines
AT kazaktch thecostofoncologymedicines
AT zlatarevaa costofoncologymedicines
AT krahtovak costofoncologymedicines
AT kazaktch costofoncologymedicines
_version_ 1718380523286429696